Investment in the Company is subject to significant risks and should only be made after a careful review of the relevant documentation and following the consultation of a legal, tax or other adviser. Investing in the Company is speculative, not suitable for all investors, and intended only for investors who are able to bear the high economic risks of such investment, which can include, but are not limited to, loss of all or a substantial portion of your investment. Each prospective purchaser should carefull ...

Core Insights - Enlivex Therapeutics Ltd. announced a private placement of $212 million to initiate a digital asset treasury strategy centered around RAIN token accumulation [2][7] - The company appointed Matteo Renzi, former Prime Minister of Italy, to its board of directors, effective November 24, 2025 [1][4] Financial Details - The private investment in public equity (PIPE) involves the purchase of 212 million ordinary shares at $1.00 per share, representing an 11.5% premium from the closing price on November 21, 2025 [2] - The expected aggregate gross proceeds from this transaction are approximately $212 million, funded in a combination of USD and USDT [2] Business Strategy - Enlivex aims to implement the first RAIN prediction markets token treasury strategy while maintaining focus on its core business operations [2][7] - The RAIN protocol is designed to be a decentralized predictions and options platform, allowing users to create and trade custom options on various markets [3] Market Context - Enlivex will be the first publicly-listed company to adopt a treasury strategy centered on RAIN, positioning itself to provide investors with exposure to this digital asset [7] - The company is also focused on the late-stage clinical development of AllocetraTM, a novel therapy for osteoarthritis, which affects over 32.5 million Americans and 300 million individuals globally [8]